PRIMARY BREAST CANCER THERAPY GROUP

作为初级乳腺癌治疗小组的参与机构 (NSABP)，我们提供了进入各种方案的患者的数据， 并将继续向B-06、11、12、13、14、 C-01和R-01。本申请寻求资金：(A)允许 在持续的方案中继续为患者积累费用；(B)参与 NSABP与本报告的评价和执行有关的活动 试验，新方案的设计，规划未来，教育 增加病人收入并与总部合作；(C) 参与NSABP接受的临床研究，特别是 与辅助性治疗相关的临床研究 (4)调查影响患者依从性的因素 治疗方案。通过对所有患者按不同方案进行随访 也将是一项必不可少的活动。协议B-06是一个试验，以进行比较 节段性乳房切除加全乳房切除术的价值。我们的努力将 针对社区医院和肿瘤科团队 没有为这项非常重要的研究贡献病人。我们已经制定了一个计划 每四个月举办一次工作坊，介绍社区 向外科医生传授必要的技术。B-11和12号议定书评估 对II期乳腺癌患者采用更积极的治疗。在……里面 在这项试验中，我们对接受治疗的患者进行了特殊评估 阿霉素。心脏病小组将评估每一位服用这种药物的患者。 在治疗前和治疗后定期使用非侵入性 技巧。这一点非常重要，因为 我们的患者的表现状态可能会因意外而改变 心脏毒性。B-13和14方案将研究I期和14期患者 治疗与不治疗将根据他们的ER状态进行测试。 我们将一如既往地为 原发性结直肠癌的辅助治疗方案。最后，一个目标是 这项协议是为了增加我们的多学科方法 机构参与临床试验，并让尽可能多的社区医生参与进来 尽可能地提高患者的收入并创造一个环境 对收集有关乳房和肠道的重要生物学数据至关重要 癌症。

As participating institution in the primary breast cancer therapy group (NSABP), we have contributed data from patients entering various protocols, and will continue to contribute data to protocols B-06, 11, 12, 13, 14, C-01 and R-01. The present application seeks funding: (a) to permit continued patient accrual in on-going protocols; (b) to participate in the NSABP activities relating to evaluation and execution of the present trials, design of new protocols, planning for the future, education for increase of patient accrual and cooperation with the headquarters; (c) participation in clinical research accepted by NSABP and particularly clinical investigation related to the effect of adjuvant treatment on our own patients; (4) investigating factors that affect compliance with therapeutic regimen. Though follow-up of all patients on various protocols will be an essential activity as well. Protocol B-06 is a trial to compare the worth of segmental mastectomy with total mastectomy. Our efforts will be directed toward those community hospitals and oncology teams which have not contributed patients to this very important study. We have made a plan to hold workshops every four months which will introduce the community surgeons to the required techniques. Protocols B-11 and 12 evaluate patients with breast cancer Stage II using more aggressive treatment. In this trial we are performing special evaluations of the patients receiving Adriamycin. A cardiology team will evaluate every patient on this drug before treatment and thereafter at periodic intervals using non-invasive techniques. This is of great importance because of the excellent performance status of our patients which may be altered by unexpected cardiotoxicity. Protocols B-13 and 14 will study patients with Stage I and treatment -vs- no treatment will be tested according to their ER status. We will continue to make a substantial contribution as in the past to the adjuvant protocols for primary colo-rectal carcinoma. Finally, an aim of this protocol is to increased the multidisciplinary approach of our institution in clinical trials, and to involve as many community physicians as possible to enhance patient accrual and to create an environment essential to the gathering of important biological data on breast and bowel cancer.